Patents by Inventor David S. Block

David S. Block has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180244772
    Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. The invention involves stradomers that increase multimerization and bind preferentially to complement and that are useful in the treatment and prevention of disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 30, 2018
    Inventors: David S. BLOCK, Henrik OLSEN
  • Publication number: 20180186862
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • Patent number: 9926362
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: March 27, 2018
    Assignees: Gliknik Inc., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Publication number: 20180002388
    Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc?Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.
    Type: Application
    Filed: July 5, 2017
    Publication date: January 4, 2018
    Inventors: David S. BLOCK, Henrik OLSEN
  • Publication number: 20170218049
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization.
    Type: Application
    Filed: April 10, 2017
    Publication date: August 3, 2017
    Inventors: Scott E. STROME, Dan H. SCHULZE, David S. BLOCK, Henrik OLSEN
  • Publication number: 20170008951
    Abstract: The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.
    Type: Application
    Filed: September 7, 2016
    Publication date: January 12, 2017
    Inventors: David S. BLOCK, Henrik OLSEN
  • Publication number: 20160355570
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 30, 2016
    Publication date: December 8, 2016
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Patent number: 9512208
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: December 6, 2016
    Assignees: GLIKNIK INC., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Patent number: 9512210
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: December 6, 2016
    Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Publication number: 20160280768
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Publication number: 20150056185
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 20, 2014
    Publication date: February 26, 2015
    Applicants: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
  • Publication number: 20140335075
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 13, 2014
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block
  • Publication number: 20140105913
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: September 20, 2013
    Publication date: April 17, 2014
    Applicants: GLIKNIK, INC., University of Maryland, Baltimore
    Inventors: Scott E. STROME, Dan H. Schulze, David S. Block
  • Patent number: 8680237
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 25, 2014
    Assignees: Gliknik Inc., University of Maryland, Baltimore
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Publication number: 20130156765
    Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.
    Type: Application
    Filed: July 28, 2011
    Publication date: June 20, 2013
    Inventors: David S. Block, Henrik Olsen
  • Publication number: 20120309941
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 6, 2012
    Applicants: GLIKNIK, INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: SCOTT E. STROME, DAN H. SCHULZE, DAVID S. BLOCK
  • Publication number: 20100239633
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Application
    Filed: May 30, 2008
    Publication date: September 23, 2010
    Applicant: UNIVERSITY OF MARYLAND BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block